LamKap Bio alpha AG is a LamKap Bio group program that researches, develops and manufactures fully human bispecific antibodies for the treatment of solid tumours. The approach redirects patients' immune effector cells (macrophages, T cells and natural killer cells) to target cancer cells; the pipeline includes candidates with target combinations such as CEA×CD3, CEA×CD28 and CEA×CD47.
AI-generated
Offering
Products & services
Industry:Research & Development
✓ Offered
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Fully human bispecific antibodies for cancer treatment in discovery and preclinical development, including T-cell retargeting and costimulatory antibody programmes against solid tumors.
NILK-2301 Program
CEA x CD3 bispecific antibody in IND/CTA enabling, targeting CEACAM5-expressing solid tumors and advancing into Phase I study.
NILK-3301 Program
CEA x CD28 bispecific antibody in preclinical development for solid tumors, designed to provide a T-cell costimulatory signal restricted by CEA on tumor cells.
Knowledge
No knowledge articles yet
Once LamKap Bio alpha AG has claimed this profile, we'll publish editorial articles and case studies here together.